These complex interactions between CD36+ CAFs and MDSCs contribute to HCC’s resistance to immunotherapy, but the CD36 inhibitor SSO (sulfo-N-succinimidyl oleate) significantly improves the efficacy of anti-PD-1 therapy[27]. The gene discussed is CD36; the disease is hepatocellular carcinoma.